KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Raw Materials (2023 - 2025)

Aurinia Pharmaceuticals' Raw Materials history spans 3 years, with the latest figure at $658000.0 for Q4 2025.

  • For Q4 2025, Raw Materials fell 61.34% year-over-year to $658000.0; the TTM value through Dec 2025 reached $658000.0, down 61.34%, while the annual FY2025 figure was $658000.0, 61.34% down from the prior year.
  • Raw Materials reached $658000.0 in Q4 2025 per AUPH's latest filing, down from $771000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.7 million in Q4 2023 to a low of $658000.0 in Q4 2025.
  • Average Raw Materials over 3 years is $1.1 million, with a median of $771000.0 recorded in 2025.
  • Peak YoY movement for Raw Materials: dropped 2.52% in 2024, then crashed 61.34% in 2025.
  • A 3-year view of Raw Materials shows it stood at $1.7 million in 2023, then dropped by 2.52% to $1.7 million in 2024, then tumbled by 61.34% to $658000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Raw Materials are $658000.0 (Q4 2025), $771000.0 (Q3 2025), and $771000.0 (Q2 2025).